Company Overview
Company Type: Private Company
Website: www.alethiabio.com
Number of Employees: -
Year Founded: 2002
Total Amount Raised (CAD mm)†: 21.97
Total Rounds of Funding**:5
Latest Post-Money Valuation ($ mm) -
Latest Pre-Money Valuation ($ mm) -
† This number reflects the estimated value of the total new money raised through private placement rounds.
** This value is an estimate of the total number of funding rounds this company has received.


Business Description
Alethia Biotherapeutics Inc., a biotechnology company, engages in the discovery and development of therapeutic monoclonal antibodies (mAb) against highly-disease tissue specific novel clinically-relevant targets. The company focuses on bone loss in acute disorders, invasive carcinomas, and cancer-associated epithelial-to-mesenchymal transition. Its products include AB-25E9, a bone antiresorptive and humanized IgG2 that inhibits the function of Siglec-15 and is used for the treatment of patients with acute bone loss; AB-3A4, an antibody-drug conjugate (ADC) representing a completely new therapeutic approach for treatment of invasive carcinomas; and AB-16B5, an humanized IgG2 monoclonal antibody and EMT inhibitor that targets tumor-associated secreted clusterins. Alethia Biotherapeutics Inc. was founded in 2002 and is based in Montreal, Canada.


Financial Information (Currency: CAD, in mm)
Total Revenue
-
Operating Income
-
Total Assets
-
Gross Profit
-
EBITDA
-
Total Debt
-
Net Income
-
Estimated Number of Employees
-
Net Debt
-
* Hover over data point numbers for date and source.

Key Professionals
Name
Title
Cornellier, Yves
Chief Executive Officer, President and Director
Filion, Mario
Chief Scientific Officer and Executive Vice President
Jolivet, Jacques 
Chief Medical Officer

Key Board Members
Name
Title
Cornellier, Yves
Chief Executive Officer, President and Director
Chamberlain, Paul
Member of Scientific Advisory Board
Eigl, Bernie
Member of Scientific Advisory Board
Goltzman, David
Member of Scientific Advisory Board
Hirte, Hal
Member of Scientific Advisory Board
Lacasse, Louis P.
Director
Lesniewski, Richard R.
Member of Scientific Advisory Board
Von Hoff, Daniel Douglas
Member of Scientific Advisory Board


Primary Industry Classification
Biotechnology


Primary Office Location
141, Président-Kennedy Avenue Suite SB-5100 | Montreal, QC | H2X 1Y4 | Canada
Phone: 514-858-7666   Fax: 514-858-5333

Current and Pending Investors
Investor
Initial Investment Date
Stake Type
Current Stake Amount
Round(s)
Cellscript, LLC
Nov-01-2012
Unknown
-
Growth
Epicentre Technologies Corp.
Apr-23-2009
Unknown
-
Series A
Génome Québec
Sep-05-2002
Minority
-
Venture

Prior Investors
AgeChem Venture Fund, L.P., Amorchem, BDC Capital Inc., BDC Health Venture Fund, GO Capital, L.P.


Company Notes
No Company Notes exist.


Strategy Notes
No Strategy Notes exist.


Last 5 Transactions
Announced Date
Closed Date
Transaction Type
Role
Target
Buyer/Investors
Sellers
Size($mm)
Nov-1-2012
Nov-1-2012
Private Placement
Target
Alethia Biotherapeutics Inc.
BDC Capital Inc.,Amorchem,Cellscript, LLC Buyer Funds:GO Capital, L.P., AgeChem Venture Fund, L.P.

4.71
Sep-7-2010
Sep-7-2010
Private Placement
Target
Alethia Biotherapeutics Inc.
BDC Capital Inc.,Epicentre Technologies Corp.,Amorchem Buyer Funds:GO Capital, L.P., AgeChem Venture Fund, L.P.

9.19
Apr-23-2009
Apr-23-2009
Private Placement
Target
Alethia Biotherapeutics Inc.
BDC Capital Inc.,Epicentre Technologies Corp. Buyer Funds:GO Capital, L.P.

1.79
Apr-03-2008
Apr-03-2008
Private Placement
Target
Alethia Biotherapeutics Inc.
BDC Capital Inc. Buyer Funds:GO Capital, L.P.

2.38
Sep-5-2002
Sep-5-2002
Private Placement
Target
Alethia Biotherapeutics Inc.
Génome Québec

3.96
* denotes that the relationship is proprietary


Last 5 Key Developments
Date
Event Type
Headline
May-21-2020
Product-Related Announcements
Alethia Biotherapeutics Announces Receipt of FDA Authorization to Begin Phase 2 Development for its EMT Inhibitor, AB-16B5
Nov-02-2019
Company Conference Presentations
Alethia Biotherapeutics Inc. Presents at 20th Annual Global Chinese Financial Forum, Nov-02-2019 12:30 PM
Mar-09-2015
Company Conference Presentations
Alethia BioTherapeutics Inc. Presents at BIO-Europe Spring 2015, Mar-09-2015
Feb-17-2015
Product-Related Announcements
Alethia Biotherapeutics Inc. Submits a Clinical Trial Application for a Phase I Study with AB-16B5
Oct-08-2013
Company Conference Presentations
Alethia BioTherapeutics Inc. Presents at 12th Annual BIO Investor Forum, Oct-08-2013


Advisors
Private Placement Advisors
Morgan Joseph TriArtisan LLC


Last 10 Investment Research Documents
Contributor
Analyst
Date/Time
Company
Headline
Type
Pages
GlobalData

Sep 14, 2023 07:11 PM
Alethia Biotherapeutics Inc.
Alethia Biotherapeutics Inc
Reports
44
GlobalData

Sep 16, 2022 07:05 AM
Alethia Biotherapeutics Inc.
Alethia Biotherapeutics Inc
Reports
44
GlobalData

Jun 16, 2022 11:40 PM
Alethia Biotherapeutics Inc.
Alethia Biotherapeutics Inc
Reports
44
GlobalData

Mar 14, 2022 03:28 AM
Alethia Biotherapeutics Inc.
Alethia Biotherapeutics Inc
Reports
44
GlobalData

Dec 15, 2021 01:32 AM
Alethia Biotherapeutics Inc.
Alethia Biotherapeutics Inc
Reports
31
GlobalData

Sep 16, 2021 04:05 AM
Alethia Biotherapeutics Inc.
Alethia Biotherapeutics Inc
Reports
20
GlobalData

Jun 11, 2021 02:16 PM
Alethia Biotherapeutics Inc.
Alethia Biotherapeutics Inc
Reports
20
GlobalData

Mar 11, 2021 10:51 PM
Alethia Biotherapeutics Inc.
Alethia Biotherapeutics Inc
Reports
20
GlobalData

Dec 10, 2020 10:47 PM
Alethia Biotherapeutics Inc.
Alethia Biotherapeutics Inc
Reports
20
Infinata, Inc.
Infinata Research
Sep 15, 2020 07:05 AM
Alethia Biotherapeutics Inc.
Alethia Biotherapeutics, Inc. - Company Report
Reports
8


S&P Global Ratings Credit Ratings
No S&P Global Ratings Credit Ratings data available. 


News Headlines
No News is currently available for the selected sources.


Company Coverage
This company is not on any Coverage List.

Products
Recombinant Monoclonal Antibodies (Future)

Key Board Members Details
Name
Title
Phone
Fax
Email
Cornellier, Yves
Chief Executive Officer, President and Director
514-858-7666
514-858-5333
ycornellier@alethiabio.com
Chamberlain, Paul
Member of Scientific Advisory Board
514-858-7666
514-858-5333
-
Eigl, Bernie
Member of Scientific Advisory Board
514-858-7666
514-858-5333
-
Goltzman, David
Member of Scientific Advisory Board
514-858-7666
514-858-5333
-
Hirte, Hal
Member of Scientific Advisory Board
514-858-7666
514-858-5333
-
Lacasse, Louis P.
Director
(514) 849-7994
(514) 849-5191
louis@genechem.com
Lesniewski, Richard R.
Member of Scientific Advisory Board
514-858-7666
514-858-5333

Von Hoff, Daniel Douglas
Member of Scientific Advisory Board
514-858-7666
514-858-5333

* denotes that the relationship is proprietary

Key Executives and Professionals Details
Name
Title
Phone
Fax
Email
Cornellier, Yves
Chief Executive Officer, President and Director
514-858-7666
514-858-5333
ycornellier@alethiabio.com
Filion, Mario
Chief Scientific Officer and Executive Vice President
514-858-7666
514-858-5333
mariof@alethiabio.com
Jolivet, Jacques 
Chief Medical Officer
514-858-7666
514-858-5333

* denotes that the relationship is proprietary

S&P Credit Ratings and Research provided by 
No content (including ratings, credit-related analyses and data, valuations, model, software or other application or output therefrom) or any part thereof (Content) may be modified, reverse engineered, reproduced or distributed in any form by any means, or stored in a database or retrieval system, without the prior written permission of S&P Global Market Intelligence or its affiliates (collectively, S&P Global). The Content shall not be used for any unlawful or unauthorized purposes. S&P Global and any third-party providers, as well as their directors, officers, shareholders, employees or agents (collectively S&P Global Parties) do not guarantee the accuracy, completeness, timeliness or availability of the Content. S&P Global Parties are not responsible for any errors or omissions (negligent or otherwise), regardless of the cause, for the results obtained from the use of the Content, or for the security or maintenance of any data input by the user. The Content is provided on an "as is" basis. S&P GLOBAL PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT THE CONTENT’S FUNCTIONING WILL BE UNINTERRUPTED OR THAT THE CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S&P Global Parties be liable to any party for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees, or losses (including, without limitation, lost income or lost profits and opportunity costs or losses caused by negligence) in connection with any use of the Content even if advised of the possibility of such damages.

Credit-related and other analyses, including ratings, and statements in the Content are statements of opinion as of the date they are expressed and not statements of fact. S&P Global Market Intelligence’s opinions, analyses and rating acknowledgment decisions (described below) are not recommendations to purchase, hold, or sell any securities or to make any investment decisions, and do not address the suitability of any security. S&P Global Market Intelligence assumes no obligation to update the Content following publication in any form or format. The Content should not be relied on and is not a substitute for the skill, judgment and experience of the user, its management, employees, advisors and/or clients when making investment and other business decisions. S&P Global Market Intelligence does not act as a fiduciary or an investment advisor except where registered as such. While S&P Global Market Intelligence has obtained information from sources it believes to be reliable, S&P Global Market Intelligence does not perform an audit and undertakes no duty of due diligence or independent verification of any information it receives.

S&P Global keeps certain activities of its divisions separate from each other in order to preserve the independence and objectivity of their respective activities. As a result, certain divisions of S&P Global may have information that is not available to other S&P Global divisions. S&P Global has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with each analytical process.

S&P Global Ratings does not contribute to or participate in the creation of credit scores generated by S&P Global Market Intelligence. Lowercase nomenclature is used to differentiate S&P Global Market Intelligence PD credit model scores from the credit ratings issued by S&P Global Ratings.

S&P Global may receive compensation for its ratings and certain analyses, normally from issuers or underwriters of securities or from obligors. S&P Global reserves the right to disseminate its opinions and analyses. S&P Global's public ratings and analyses are made available on its Web sites, www.standardandpoors.com (free of charge), and www.capitaliq.com (subscription), and may be distributed through other means, including via S&P Global publications and third-party redistributors. Additional information about our ratings fees is available at www.standardandpoors.com/usratingsfees.
Regulatory News Service data provided by 
